Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early ...
The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...
Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...
AM ET / 6:00 AM MT / 1:00 PM BST. The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results